Biomed Central Ltd

SHERPA: Unknown

People

  1. Hirschhorn Cymerman
    Hirschhorn Cymerman
  2. Panageas
    Panageas
  3. Postow
    Postow
  4. Budhu
    Budhu
  5. Chawla
    Chawla
  6. George
    George
  7. Houghton
    Houghton
  8. Jayaprakasam
    Jayaprakasam
  9. Kurtansky
    Kurtansky
  10. Lin
    Lin

Groups

  1. Department of Medicine (9)
  2. Hematologic Malignancies, Division of (9)
  3. Hematology-Oncology Fellows (9)
  4. Melanoma and Immunotherapeutics Service (9)
  5. Solid Tumor Oncology Division (9)
  6. Weinberg Fellows (9)
  7. Division of Subspecialty Medicine (4)
  8. Biostatistics Service (3)
  9. Dermatology Service (3)
  10. Dermatology (3)
Search Within
  1. "Allison Betof Warner"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
  3. Guidelines (1)
  4. Review (1)
Groups
  1. Department of Medicine (9)
  2. Hematologic Malignancies, Division of (9)
  3. Hematology-Oncology Fellows (9)
  4. Melanoma and Immunotherapeutics Service (9)
  5. Solid Tumor Oncology Division (9)
  6. Weinberg Fellows (9)

More Groups

People
  1. Allison Betof Warner (9)
  2. Jedd Wolchok (3)
  3. Daniel Hirschhorn Cymerman (2)
  4. Katherine Panageas (2)
  5. Margaret Callahan (2)
  6. Mario Lacouture (2)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (4)
  4. 2018 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (8)
  2. Journal of Translational Medicine (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining D-irAEs: Consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
    Journal Article

    Chen, S. T.; Semenov, Y. R.; Alloo, A.; Bach, D. Q.; Betof Warner, A.; Bougrine, A.; Burton, L.; Cappelli, L. C.; Castells, M.; Cohen, J.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of talen-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Betof, A.; Wise-Draper, T.; He, K.; Sarnaik, A.; Thompson, J.; Finckenstein, F.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model
    Meeting Abstract

    George, M.; Betof, A.; Merghoub, T.; Hamadene, L.; Hirschhorn, D.; Houghton, A.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
    Review

    Ascierto, P. A.; Warner, A. B.; Blank, C.; Caracò, C.; Demaria, S.; Gershenwald, J. E.; Khushalani, N. I.; Long, G. V.; Luke, J. J.; Mehnert, J. M.; more...
    Journal of Translational Medicine (2022)

    Fulltext@MSK | Save
  • Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Journal Article

    Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy
    Journal Article

    Halle, B. R.; Betof Warner, A.; Zaman, F. Y.; Haydon, A.; Bhave, P.; Dewan, A. K.; Ye, F.; Irlmeier, R.; Mehta, P.; Kurtansky, N. R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
    Guidelines

    Guidon, A. C.; Burton, L. B.; Chwalisz, B. K.; Hillis, J.; Schaller, T. H.; Amato, A. A.; Betof Warner, A.; Brastianos, P. K.; Cho, T. A.; Clardy, S. L.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save